128 related articles for article (PubMed ID: 9464717)
1. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens.
Cushing KL; Weiss NS; Voigt LF; McKnight B; Beresford SA
Obstet Gynecol; 1998 Jan; 91(1):35-9. PubMed ID: 9464717
[TBL] [Abstract][Full Text] [Related]
2. Estrogens, progesterone, and endometrial cancer.
Jick SS; Walker AM; Jick H
Epidemiology; 1993 Jan; 4(1):20-4. PubMed ID: 8380547
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy and endometrial cancer risk: a meta-analysis.
Grady D; Gebretsadik T; Kerlikowske K; Ernster V; Petitti D
Obstet Gynecol; 1995 Feb; 85(2):304-13. PubMed ID: 7824251
[TBL] [Abstract][Full Text] [Related]
4. Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma.
Herrinton LJ; Weiss NS
Ann Epidemiol; 1993 May; 3(3):308-18. PubMed ID: 8275205
[TBL] [Abstract][Full Text] [Related]
5. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States).
Green PK; Weiss NS; McKnight B; Voigt LF; Beresford SA
Cancer Causes Control; 1996 Nov; 7(6):575-80. PubMed ID: 8932917
[TBL] [Abstract][Full Text] [Related]
6. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.
Beresford SA; Weiss NS; Voigt LF; McKnight B
Lancet; 1997 Feb; 349(9050):458-61. PubMed ID: 9040575
[TBL] [Abstract][Full Text] [Related]
7. Risk of endometrial cancer following estrogen replacement with and without progestins.
Weiderpass E; Adami HO; Baron JA; Magnusson C; Bergström R; Lindgren A; Correia N; Persson I
J Natl Cancer Inst; 1999 Jul; 91(13):1131-7. PubMed ID: 10393721
[TBL] [Abstract][Full Text] [Related]
8. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group.
Brinton LA; Hoover RN
Obstet Gynecol; 1993 Feb; 81(2):265-71. PubMed ID: 8380913
[TBL] [Abstract][Full Text] [Related]
9. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study.
Kaufman DW; Palmer JR; de Mouzon J; Rosenberg L; Stolley PD; Warshauer ME; Zauber AG; Shapiro S
Am J Epidemiol; 1991 Dec; 134(12):1375-85; discussion 1396-401. PubMed ID: 1663700
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease.
Weiss JM; Saltzman BS; Doherty JA; Voigt LF; Chen C; Beresford SA; Hill DA; Weiss NS
Am J Epidemiol; 2006 Jul; 164(1):56-62. PubMed ID: 16675538
[TBL] [Abstract][Full Text] [Related]
11. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy.
Chubak J; Doherty JA; Cushing-Haugen KL; Voigt LF; Saltzman BS; Hill DA; Beresford SA; Weiss NS
Cancer Causes Control; 2007 Nov; 18(9):1001-7. PubMed ID: 17653829
[TBL] [Abstract][Full Text] [Related]
12. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
Chlebowski RT; Anderson GL; Sarto GE; Haque R; Runowicz CD; Aragaki AK; Thomson CA; Howard BV; Wactawski-Wende J; Chen C; Rohan TE; Simon MS; Reed SD; Manson JE
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26668177
[TBL] [Abstract][Full Text] [Related]
13. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
[TBL] [Abstract][Full Text] [Related]
14. Case-control study of endogenous steroid hormones and endometrial cancer.
Potischman N; Hoover RN; Brinton LA; Siiteri P; Dorgan JF; Swanson CA; Berman ML; Mortel R; Twiggs LB; Barrett RJ; Wilbanks GD; Persky V; Lurain JR
J Natl Cancer Inst; 1996 Aug; 88(16):1127-35. PubMed ID: 8757192
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-progestin replacement therapy and endometrial cancer.
Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
[TBL] [Abstract][Full Text] [Related]
16. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer.
Comerci JT; Fields AL; Runowicz CD; Goldberg GL
Gynecol Oncol; 1997 Mar; 64(3):425-30. PubMed ID: 9062144
[TBL] [Abstract][Full Text] [Related]
17. Menopausal hormone use and endometrial cancer, by tumor grade and invasion.
Shapiro JA; Weiss NS; Beresford SA; Voigt LF
Epidemiology; 1998 Jan; 9(1):99-101. PubMed ID: 9430277
[TBL] [Abstract][Full Text] [Related]
18. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.
Smith NL; Heckbert SR; Lemaitre RN; Reiner AP; Lumley T; Weiss NS; Larson EB; Rosendaal FR; Psaty BM
JAMA; 2004 Oct; 292(13):1581-7. PubMed ID: 15467060
[TBL] [Abstract][Full Text] [Related]
19. Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States).
Finkle WD; Greenland S; Miettinen OS; Ziel HK
Cancer Causes Control; 1995 Mar; 6(2):99-102. PubMed ID: 7749058
[TBL] [Abstract][Full Text] [Related]
20. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
